Clinical trials: AIDS Vaccines
Human Influenza
Conventional Vaccine and Intradermal Vaccine Among HIV-infected Young Subjects
Several studies have shown poor immune response to conventional influenza vaccines in HIV-infected individuals. This study was conducted expecting the more potent immunogenicity of intradermal vaccine compared with conventional…
- Trial name
- NCT02398097
- Testing
- Agripal, IDflu9μg, IDflu15μg
- Volunteers
- 88 people
- Sponsor
- Korea University Guro Hospital
HIV Infections
A Phase I Safety and Immunogenicity Trial of the Facilitated HIV-1 Gag-Pol DNA Vaccine (APL-400-047, Apollon, Inc.) Given Intramuscularly by Needle and Syringe or Biojector 2000 Needle-Free Jet Injection System in HIV-1 Uninfected Adult Volunteers
To evaluate the safety, tolerability and immunogenicity in humans of the APL-400-047 vaccine when administered intramuscularly by needle and syringe at 1 of 3 doses or by Biojector at the intermediate dose.
- Trial name
- NCT00001088
- Testing
- APL 400-047, Bupivacaine hydrochloride
- Where
- 4 sites in United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infection
Improving Immunogenicity of Influenza Vaccine in HIV Infected Individuals
The overall goal of this study is to compare the safety and immunogenicity of trivalent Fluzone® High-Dose vaccine vs the regular standard-dose (SD) in HIV infected individuals.
- Trial name
- NCT01262846
- Testing
- Fluzone®
- Where
- United States
- Volunteers
- 195 people
- Sponsor
- University of Pennsylvania
HIV Infections
Evaluating the Safety and Immunogenicity of an HIV-1 gp41 MPER-656 Liposome Vaccine in Healthy, HIV-uninfected Adult Participants
The purpose of this study is to evaluate the safety and immunogenicity of an HIV-1 gp41 MPER-656 liposome vaccine in healthy, HIV-uninfected adults.
- Trial name
- NCT03934541
- Testing
- MPER-656 Liposome Vaccine
- Where
- 6 sites in United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Study of the HIV gp120/NefTat/AS02A Vaccine to Treat Individuals With Chronic HIV-1 Infection on Highly Active Antiretroviral Therapy (HAART)
This study will test the safety and immunogenicity of the gp120/NefTat/AS02A vaccine candidate in individuals with chronic HIV-1 infection successfully treated with HAART.
- Trial name
- NCT00117429
- Testing
- HIV gp120/NefTat/AS02A Vaccine
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Marcus Altfeld, M.D., Ph.D.
HPV, Human Papilloma Virus
A Study of Reduced Dosing of the Nonavalent HPV Vaccine in Women Living With HIV
There are very little data on human papillomavirus (HPV) vaccination among the 18 million women living with HIV (WLWH) globally, who constitute a population most vulnerable to HPV and the resultant cervical cancer.
- Conditions
- HPV, Human Papilloma Virus, Human Immunodeficiency Virus
- Trial name
- NOVA-HIV (NCT05495906)
- Testing
- Nonavalent HPV vaccine
- Where
- 10 sites in Canada
- Volunteers
- 275 people, healthy volunteers welcome
- Sponsor
- University of British Columbia
HIV Infections
Study of Late Boost Strategies for HIV-uninfected Participants From Protocol RV 144
The purpose of this study is to assess safety and tolerability of late boost regimens of AIDSVAX B/E alone, ALVAC-HIV alone, or ALVAC-HIV/AIDSVAX B/E combination in HIV-uninfected participants from RV 144.
- Trial name
- NCT01435135
- Testing
- ALVAC-HIV, AIDSVAX B/E
- Where
- 2 sites in Thailand
- Volunteers
- 162 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command
Influenza, HIV
Influenza Vaccine in HIV
The purposes of this research study are: 1. to see if there is a difference in the quantity of protective influenza antibodies produced by different doses of the Fluviral vaccine 2.
- Trial name
- NCT00764998
- Testing
- Fluviral
- Where
- 13 sites in Canada
- Volunteers
- 285 people
- Sponsor
- Ottawa Hospital Research Institute
HIV
Safety and Immunogenicity of ChAdV63.HIVconsv and MVA.HIVconsv Candidate HIV-1 Vaccines in Recently HIV-1 Infected Individuals
The HIVconsv gene was constructed by assembling the 14 most conserved regions of the HIV-1 proteome into one chimaeric protein. This gene has been inserted into 2 leading non-replicating vaccine vectors: an attenuated chimpanzee…
- Trial name
- NCT01712425
- Testing
- 0-24 week prime/boost regimen, 0-8 week prime/boost regimen
- Where
- 2 sites in Spain
- Volunteers
- 48 people
- Sponsor
- IrsiCaixa
HIV Infections
Evaluating the Safety of and Immune Response to an HIV Vaccine in Healthy, HIV-Uninfected Adults in Uganda
The RV 156A clinical trial is evaluating an experimental HIV vaccine in people who are not infected with HIV. Participants in that study are randomly assigned to receive either the HIV vaccine or placebo.
- Trial name
- NCT01549509
- Testing
- VRC-HIVADV014-00-VP Vaccine
- Where
- Uganda
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Redirected High Affinity Gag-Specific Autologous T Cells for HIV Gene Therapy
This research study is being carried out to study a new way to possibly treat HIV. T-cells are one of the white blood cells used by the body to fight HIV.
- Trial name
- NCT00991224
- Testing
- WT-gag-TCR modified T cells, α/6-gag-TCR modified T cells, STI or Drug Holiday
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of Pennsylvania
HPV Infection, HIV Infection
Human Papillomavirus Infection and Knowledge and Attitudes About HPV Vaccines Among Men Who Have Sex With Men (MSM)
This is a observational study aims to assess anal and genital human papillomavirus (HPV) infection status among men who have sex with men (MSM) in China, and their knowledge and attitude about HPV vaccine.
- Conditions
- HPV Infection, HIV Infection, Syphilis
- Trial name
- NCT01300689
- Where
- China
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Chinese Academy of Medical Sciences
HIV Infections
A Study of LIPO-5 and ALVAC-HIV (vCP1452) as Possible HIV Vaccines
This study will test the immune system response to and safety of two HIV vaccines alone and in combination: ALVAC-HIV (vCP1452) and LIPO-5. ALVAC-HIV (vCP1452) uses a canarypox virus with man-made parts of HIV attached to it.
- Trial name
- NCT00076063
- Testing
- ALVAC-HIV (vCP1452), LIPO-5
- Where
- 11 sites in United States
- Volunteers
- 174 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Therapeutic Vaccination Followed by Treatment Interruption in HIV Infected Patients
The aim of this trial is to find out if immune responses to HIV can be boosted in individuals who start medicines soon after being infected.
- Trial name
- NCT00058734
- Testing
- Dendritic Cells Pulsed with HIV antigens
- Where
- United States
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV-1, HIV Infections
Safety and Immunogenicity Study of Candidate HIV-1 Vaccine Given to Healthy Infants Born to HIV-1-infected Mothers
Objectives: Primary: Safety and immunogenicity of MVA.HIVA vaccine in 20-week-old healthy Kenyan infants born to HIV-1-infected mothers.
- Trial name
- PedVacc002 (NCT00981695)
- Testing
- MVA.HIVA
- Where
- Kenya
- Volunteers
- 72 people
- Sponsor
- Medical Research Council
HIV Infections, H1N1 Influenza Virus
Safety of and Immune Response to an H1N1 Influenza Virus Vaccine in HIV Infected Children and Youth
Children and people infected with HIV are particularly susceptible to influenza infections. This study testED the safety and effectiveness of a vaccine for the new H1N1 influenza virus in children and youth infected with HIV.
- Trial name
- NCT00992836
- Testing
- Influenza A (H1N1) 2009 monovalent vaccine
- Where
- 37 sites in United States, Puerto Rico
- Volunteers
- 155 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Tuberculosis
Study of AERAS-402 in Healthy Infants
AERAS-402 will be given to infants of at least 16 weeks of age who have already been vaccinated with BCG to determine if AERAS-402 will increase protection of infants to tuberculosis.
- Trial name
- NCT01198366
- Testing
- AERAS-402 1.5 x 10^10 vp, AERAS-402 3.0 x 10^10 vp, AERAS-402 1.0 x 10^11 vp
- Where
- 7 sites in Kenya, Mozambique and 1 more
- Volunteers
- 487 people, healthy volunteers welcome
- Sponsor
- Aeras
HIV Infections, Hepatitis B
Pneumococcal Vaccine and Routine Pediatric Immunizations in HIV-Infected Children Receiving Anti-HIV Drugs
The purpose of this study is to determine if 2 doses of Pneumococcal Conjugate Vaccine (PCV) followed by 1 dose of Pneumococcal Polysaccharide Vaccine (PPV) in HIV-infected children on anti-HIV therapy is helpful and safe in…
- Conditions
- HIV Infections, Hepatitis B, Measles, Pneumococcal Infections
- Trial name
- NCT00013871
- Testing
- Diphtheria & Tetanus Toxoids & Acellular Pertussis Vaccine Adsorbed, Measles-Mumps-Rubella Vaccine (Live), Pneumococcal Vaccine, Polyvalent (23-valent)
- Where
- 40 sites in United States, Puerto Rico
- Volunteers
- 300 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV, Cancer
Immunogenicity of Fluzone HD,A High Dose Influenza Vaccine, In Children With Cancer or HIV
This is an open label-study of Fluzone HD, a high-dose form of trivalent, inactivated influenza vaccine (TIV), vs. Fluzone, a standard-dose form of TIV.
- Trial name
- NCT01205581
- Testing
- Fluzone High Dose Vaccine, Fluzone Standard Dose Vaccine
- Where
- United States
- Volunteers
- 85 people
- Sponsor
- St. Jude Children's Research Hospital
HIV Infections
Determining an Effective Site (Groin Versus Arm) for Giving HIV Vaccines
The purpose of this study is to determine the safety and immune system response to the TBC-3B HIV vaccine when it is injected either into the groin area or into the arm.
- Trial name
- NCT00056745
- Testing
- TBC-3B
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)